Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumorsAnthony W. Tolcher, D. Voliotis, Philippe Pultar et al.|Cancer Research|2021Cited by 24
Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC)Funda Meric‐Bernstam, Anthony W. Tolcher, Pavani Chalsani et al.|Cancer Research|2022Cited by 16
526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3Pavani Chalasani, Fernando Doñate, D. Voliotis et al.|Annals of Oncology|2021Cited by 1